SCHEMBL13424413

SCHEMBL13424413

CC(C)(C)[Si](C)(C)O[C@H]1CC(CBr)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.36
ACHE P22303 1/20 0.36
PDPK1 O15530 1/20 0.35
MTOR P42345 1/20 0.35
SLC6A2 P23975 1/20 0.32
SSTR1 P30872 1/20 0.32
SSTR2 P30874 1/20 0.32
SSTR4 P31391 1/20 0.32
SSTR3 P32745 1/20 0.32
SSTR5 P35346 1/20 0.32
PDE4D Q08499 1/20 0.32
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C19 P33261 1/20 0.31
THRB P10828 1/20 0.31
PSEN1 P49768 3/20 0.30
PSEN2 P49810 3/20 0.30
APH1B Q8WW43 3/20 0.30
NCSTN Q92542 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13424415 0.88 PDE4D (0.38) BCHEACHEPDPK1MTORSLC6A2
SCHEMBL13424419 0.84 BCHE (0.38) BCHEACHEPDPK1MTORSSTR1
SCHEMBL14957939 0.82 BCHE (0.40) BCHEACHESSTR1SSTR2SSTR4
SCHEMBL14107809 0.77 CTSL (0.36) BCHEACHEMAPTCYP2C19THRB
SCHEMBL4895151 0.77 CTSL (0.36) BCHEACHEMAPTCYP2C19THRB
SCHEMBL14958146 0.75 BCHE (0.36) BCHEACHEPDE4D
SCHEMBL14958147 0.75 BCHE (0.36) BCHEACHEPDE4D
SCHEMBL17644796 0.75 BCHE (0.36) BCHEACHEPDE4D
SCHEMBL21077041 0.73 PSEN1 (0.43) BCHEACHEMAPTCYP2C19PSEN1
SCHEMBL14107808 0.73 CTSL (0.37) BCHESLC6A2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299223-B2 Pseudoglycolipid and use thereof RIKEN (JP) 2012-10-30 US disclosed
US-20100062990-A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF RIKEN (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062990-A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF PNLIP, SGMS1, SGPL1 BCHE 1946/4885ACHE 3384/4885PDPK1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.